FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology. Method involves determining XPD gene polymorphisms (Lis751Gln), MMP-1 (-1607 insG), TNF (G308A). If carrying the XPD (Lis751Gln) (Lis/Lis), MMP-1 (-1607 insG) (2G/2G) and TNF (G308A) (G/A) genotypes in the combination MMP-1 (-1607 insG) (2G/2G ) predict a high probability of III or IV degree pathomorphosis in tumour tissue compared to other polymorphous variants of these genes.
EFFECT: presented is a method for predicting the effectiveness of neoadjuvant chemoradiotherapy in rectal adenocarcinoma.
1 cl, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR ORGAN-PRESERVING TREATMENT OF OPERABLE RECTAL CANCER | 2020 |
|
RU2740361C1 |
| METHOD FOR PREDICTING THE RISK OF STROKE IN MEN BASED ON GENETIC TESTING | 2017 |
|
RU2664430C1 |
| METHOD FOR PREDICTION OF POPULATION BIOTRANSFORMATION DISORDERS OF FOREIGN SUBSTANCES CAUSED BY EXPOSURE TO MAN-INDUCED CHEMICAL HABITAT FACTORS | 2012 |
|
RU2497120C1 |
| METHOD FOR PREDICTING RESPONSE TO PERIOPERATIVE CHEMOTHERAPY IN STAGE II-III GASTRIC CANCER | 2024 |
|
RU2835890C1 |
| METHOD FOR ASSESSING PRIMARY RESPONSE TO COMBINED CHEMOTHERAPY OF SPORADIC OVARIAN CANCER OF STAGES III AND IV | 2021 |
|
RU2769543C2 |
| METHOD OF TREATING RECTAL CANCER USING A PERSONALIZED APPROACH | 2018 |
|
RU2701143C1 |
| METHOD FOR COMBINED TREATMENT OF COLON CANCER | 2023 |
|
RU2820567C1 |
| METHOD FOR PREDICTING THE DEGREE OF RISK OF EXTRAPYRAMID SIDE EFFECTS DURING THE BACKGROUND OF HALOPERIDOL THERAPY IN PATIENTS WITH SCHIZOPHRENIC SPECTRUM DISORDERS | 2021 |
|
RU2771180C1 |
| METHOD FOR DETERMINING THE GENETIC PREDISPOSITION TO THE DEVELOPMENT OF MULTIDRUG-RESISTANT TUBERCULOSIS MYCOBACTERIUM TUBERCULOSIS IN HIV INFECTION | 2020 |
|
RU2750715C1 |
| METHOD OF COMBINED TREATMENT OF LOCALLY ADVANCED GASTRIC CANCER | 2020 |
|
RU2725079C2 |
